DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

BACKGROUND: Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combination with rituximab yielded high objective response rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Cendrowicz, Ewa, Jacob, Lisa, Greenwald, Shirley, Tamir, Ami, Pecker, Iris, Tabakman, Rinat, Ghantous, Lucy, Tamir, Liat, Kahn, Roy, Avichzer, Jasmine, Aronin, Alexandra, Amsili, Shira, Zorde-Khvalevsky, Elina, Gozlan, Yosi, Vlaming, Martijn, Huls, Gerwin, van Meerten, Tom, Dranitzki, Michal Elhalel, Foley-Comer, Adam, Pereg, Yaron, Peled, Amnon, Chajut, Ayelet, Bremer, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919572/
https://www.ncbi.nlm.nih.gov/pubmed/35287686
http://dx.doi.org/10.1186/s13046-022-02256-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919572/
https://www.ncbi.nlm.nih.gov/pubmed/35287686
http://dx.doi.org/10.1186/s13046-022-02256-x

Ejemplares similares